BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2006

View Archived Issues

Studies delineate armodafinil effects in patients with sleep disorders

Read More

Affymetrix and Invitrogen sign licensing agreement

Read More

Preliminary results from phase II studies of cocaine vaccine TA-CD

Read More

Azedra studied for treatment of neuroendocrine tumors

Read More

Advancis signs contract sales agreement with Innovex

Read More

Pierre Fabre and Millenia Hope team up

Read More

MediGene receives German grant for EndoTAG technology

Read More

Merrion and Roche collaborate on oral drug delivery feasibility study

Read More

Preclinical characterization of rivoglitazone and its effects on adiponectin in healthy subjects

Read More

Pharmacokinetics and efficacy of the DPP-IV inhibitor, PSN-9301, in patients with type 2 diabetes

Read More

Pharmacokinetics, safety and efficacy of BIM-51077 in dogs and patients with type 2 diabetes

Read More

Enrollment completed in Nebido PK study

Read More

Merck, Sharp & Dohme report on new GABA-A alpha3 modulators

Read More

Higher dose regimen of removab yields tumor response

Read More

Positive phase II results for ALTU-238 in growth hormone deficient adults

Read More

IND filing for study of VivaGel for prevention of genital herpes

Read More

deCODE updates pipeline progress

Read More

MorphoSys and Novartis expand therapeutic antibody collaboration

Read More

ANA-975 dosing suspended pending analysis of preclinical findings

Read More

Novelos' acute radiation syndrome proposal to be studied further by DHHS

Read More

Phase III Avastin study in advanced pancreatic cancer fails to meet endpoint

Read More

Highlights of dasatinib studies from the European Hematology Association meeting

Read More

Models show potential of hLF1-11 as anti-infective in stem cell transplant patients

Read More

Topical retapamulin effective in secondarily infected dermatitis

Read More

Exelon, first FDA approved treatment for Parkinson's disease dementia

Read More

Neutralizing GM-CSF shows potential to treat inflammatory diseases

Read More

Chemokine CCR5 receptor ligands for HIV patented by ViroChem Pharma

Read More

New treatment options for cardiovascular disorders reported in recent patent literature

Read More

Patent claims use of telithromycin in acute exacerbations of asthma

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing